← Back to Screener
Rein Therapeutics, Inc. Common Stock (RNTX)
Price$1.83
Favorite Metrics
Price vs S&P 500 (26W)26.64%
Price vs S&P 500 (4W)32.44%
Market Capitalization$49.35M
All Metrics
Book Value / Share (Quarterly)$0.61
P/TBV (Annual)8.92x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.70
Price vs S&P 500 (YTD)47.59%
EPS (TTM)$-1.84
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-1.84
EPS (Annual)$-1.96
ROI (Annual)-294.78%
Cash / Share (Quarterly)$0.12
ROA (Last FY)-206.44%
EBITD / Share (TTM)$-1.99
ROE (5Y Avg)-126.55%
Cash Flow / Share (Annual)$-0.70
P/B Ratio2.92x
P/B Ratio (Quarterly)1.80x
Net Income / Employee (Annual)$-5
ROA (TTM)-103.38%
EPS Incl Extra (Annual)$-1.96
Current Ratio (Annual)0.70x
Quick Ratio (Quarterly)0.66x
3-Month Avg Trading Volume0.15M
52-Week Price Return6.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)2.21x
Asset Turnover (Annual)1.39x
52-Week High$2.40
EPS Excl Extra (Annual)$-1.96
26-Week Price Return35.38%
Quick Ratio (Annual)0.66x
13-Week Price Return57.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.70x
Enterprise Value$46.134
Revenue / Employee (Annual)$0
Pretax Margin (Annual)14.72%
Cash / Share (Annual)$0.12
3-Month Return Std Dev78.56%
Net Income / Employee (TTM)$-5
ROE (Last FY)-294.78%
EPS Basic Excl Extra (Annual)$-1.96
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.84
ROI (TTM)-123.90%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.12
Price vs S&P 500 (52W)-28.43%
Year-to-Date Return51.72%
5-Day Price Return13.55%
EPS Normalized (Annual)$-1.96
ROA (5Y Avg)-100.10%
Net Profit Margin (Annual)14.72%
Month-to-Date Return35.38%
EBITD / Share (Annual)$-1.99
Operating Margin (Annual)14.68%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-126.55%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.84
P/TBV (Quarterly)8.92x
P/B Ratio (Annual)1.80x
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)54.28%
Beta1.64x
Revenue / Share (TTM)$0.00
ROE (TTM)-123.90%
52-Week Low$1.02
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RNTXRein Therapeutics, Inc. Common Stock | — | — | — | — | $1.83 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Rein Therapeutics develops therapies for orphan pulmonary and fibrosis indications with significant unmet medical need. The company has two Phase 2-ready candidates: LTI-03, a peptide for idiopathic pulmonary fibrosis, and LTI-01, a proenzyme for loculated pleural effusion—an indication with no approved treatments. Both programs have completed Phase 1b proof-of-concept and Phase 2a dose-ranging trials.